Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Partnership with Industry (BPI) (U01 Clinical Trial Optional)
Notice Number:
NOT-EB-21-023

Key Dates

Release Date:
December 27, 2021
Estimated Publication Date of Funding Opportunity Announcement:
February 28, 2022
First Estimated Application Due Date:
May 26, 2022
Earliest Estimated Award Date:
April 01, 2023
Earliest Estimated Start Date:
April 01, 2023
Related Announcements

NOT-EB-21-024: Notice of Intent to Publish a Funding Opportunity Announcement for Bioengineering Partnership with Industry (BPI) (U01 Clinical Trial Not Allowed)

Issued by

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Purpose

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Cancer Institute (NCI), National Eye Institute (NEI), National Institute on Aging (NIA), and National Institute of Environmental Health Sciences (NIEHS) intend to reissue a modified version of the Bioengineering Research Partnership Funding Opportunity Announcements (FOA)s Bioengineering Research Partnerships (U01 Clinical Trial Not Allowed) and Bioengineering Research Partnerships (U01 Clinical Trial Required) with new FOAs entitled, Bioengineering Partnership with Industry (BPI), whose goal is to drive the development and speed the adoption of promising tools and technologies that can address important biomedical problems for which insufficient or no solutions exist. The use of engineering principles is encouraged to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need.

A key change compared with prior Bioengineering Research Partnership FOAs is that BPI applications must include at least one academic and one industrial organization.

The purpose of the BPI FOA will be to encourage applications to: 1) establish a robust engineering solution to a problem in biomedical research or the practice of medicine; 2) develop a strategic alliance of multi-disciplinary partners based on a well-defined leadership plan; and 3) realize a specific endpoint within 5-10 years based on a detailed plan with a timeline and quantitative milestones.

The areas of research encouraged in this initiative must be consistent with the mission of the IC's participating in the BPI funding opportunity.

This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

The FOA is expected to be published in February 2022 with an expected application due date in May 2022.

This FOA will utilize the U01 activity code.

Research Initiative Details
Funding Information

TBD

Estimated Total Funding

TBD

Expected Number of Awards

Award number is contingent on NIH appropriations and submission of meritorious applications.

Estimated Award Ceiling

Application budgets are not limited but need to reflect the actual needs of the proposed project.

Primary Assistance Listing Number(s)

93.286

Anticipated Eligible Organizations
Public/State Controlled Institution of Higher Education
Private Institution of Higher Education
Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education)
Small Business
For-Profit Organization (Other than Small Business)
State Government
Indian/Native American Tribal Government (Federally Recognized)
County governments
Independent school districts
Public housing authorities/Indian housing authorities
Indian/Native American Tribally Designated Organization (Native American tribal organizations (other than Federally recognized tribal governments)
U.S. Territory or Possession
Indian/Native American Tribal Government (Other than Federally Recognized)
Non-domestic (non-U.S.) Entity (Foreign Organization)
Regional Organization
Eligible Agencies of the Federal Government

Applications are not being solicited at this time. 

Inquiries

Please direct all inquiries to:

I. George Zubal, Ph.D.

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

301-827-5168